Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Patel, N. Orie, L. Clapp (London, United Kingdom). Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1093

Member's Comments

No comment yet.

Related content which might interest you: Dexamethasone induces anti-remodelling effects in rat pulmonary arterial smooth muscle cells Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 In vitro effects of vasodilatory drugs on BMPR2-silenced pulmonary microvascular endothelial cell function Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Bosentan stimulates the expression of cell cycle inhibitor p27(kip1) in pulmonary artery smooth muscle cells (PASMC) Source: Annual Congress 2007 - Animal and ex vivo models of airway inflammation Year: 2007 Increased p130Cas activity induces smooth muscle cell proliferation and migration in idiopathic pulmonary arterial hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Effect of endothelin-1 and bosentan on gene expressions in the cultured pulmonary artery smooth muscle cells Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 The effect of ASK1 inhibition on hypoxia-induced pulmonary artery fibroblast activation and associated paracrine effects on vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Involvement of pulmonary artery smooth muscle cell apoptosis in simvastatin-induced regression of hypoxic pulmonary hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Shroom expression is attenuated in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 871-880 Year: 2008